Valye reports for unlimited access

Newbridge Acquisition Ltd is a special purpose acquisition company incorporated to effect a merger or acquisition with one or more businesses. The company completed its IPO on February 2, 2026, issuing units consisting of Class A ordinary shares and rights, raising gross proceeds of $57.5 million including over-allotment. The proceeds are held in a trust account pending completion of an initial business combination. The company has no operating subsidiaries or revenues and has not yet identified a target business. Management and board members have significant ties to China, and while the company is not specifically targeting Chinese companies, it may consider targets with significant ties to China, which may subject the combined entity to PRC regulatory risks. The company targets small-cap companies with growth potential in emerging markets and industries such as green energy, advanced technologies, and AI applications. It has 15 months from IPO closing to complete a business combination, with possible extensions. The company is an emerging growth company and faces risks related to its early stage, regulatory environment, and financial condition.

Solo Brands, Inc. is a publicly traded company on the NYSE under the ticker SBDS. The company undertook a reverse stock split in mid-2025 to regain compliance with NYSE listing standards and had its trading reinstated shortly thereafter. Financial disclosures indicate the company has significant liquidity with a current ratio near 3.0 as of the end of 2025, but it has reported substantial net losses and negative earnings per share in recent years. The company has restructured its debt through a refinancing amendment in 2025 and completed a corporate simplification merger effective January 2026. The company is classified as an emerging growth company. Detailed information on the company's industry, product lines, and customer base is not publicly disclosed in the available filings.

Richmond Mutual Bancorporation Inc is a regional bank holding company headquartered in Maryland, serving primarily Indiana and Ohio through its subsidiary First Bank Richmond. The bank offers a comprehensive range of financial services including commercial, real estate, consumer lending, and lease financing. Its lease portfolio is diversified across various equipment types and geographic locations, supported by a network of brokers and third-party originators. The company also provides trust and wealth management services. Revenue is primarily generated from net interest income, supplemented by fees and investment income. The company is regulated by multiple federal and state agencies and adheres to evolving accounting standards such as CECL. It maintains a strong focus on cybersecurity and operational risk management. Recent strategic initiatives include a merger with The Farmers Bancorp and consistent dividend payments to shareholders.

EQUATOR Beverage Company develops, produces, distributes, and markets a portfolio of ready-to-drink and sparkling energy beverages. Its products are Non-GMO Project Verified and USDA Organic certified, targeting consumers seeking functional, clean-label, and premium beverage options. The flagship product is MOJO Coconut Water, a hydration beverage with essential electrolytes and vitamins, free from preservatives and suitable for various dietary preferences. The company emphasizes sustainability through 100% recyclable packaging and plant-based renewable resources. Distribution spans North America, the Caribbean, and Bermuda via third-party distributors and retail channels. EQUATOR operates a capital-efficient business model leveraging outsourcing and technology to scale operations with a lean internal workforce. The company sells over 8 million units annually and focuses on disciplined growth and supply chain stability.

Xilio Therapeutics, Inc. operates in the biopharmaceutical sector, developing tumor-activated immuno-oncology therapies. The company is in clinical stages of development, with ongoing Phase 2 trials such as Vilastobart combined with Atezolizumab for metastatic MSS colorectal cancer. Xilio has raised capital through public offerings and warrant exercises to support its operations. Financial disclosures indicate a net loss and a strong liquidity position as of the end of 2025. The company is publicly traded on Nasdaq under the ticker XLO.

Cabaletta Bio, Inc. focuses on developing innovative engineered T cell therapies for autoimmune diseases using its proprietary CABA® platform, specifically the CARTA approach. The lead product candidate, rese-cel, is a fully human CD19-CAR T cell therapy designed to achieve transient and deep B cell depletion with a single infusion, aiming to reset the immune system and provide durable clinical responses without chronic therapy. The company is conducting multiple Phase 1/2 clinical trials across a range of autoimmune diseases including systemic lupus erythematosus, myositis subtypes, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. Registrational trials have been initiated for dermatomyositis and anti-synthetase syndrome with plans for regulatory submissions. Manufacturing is supported by partnerships with several CDMOs and includes efforts to implement automated manufacturing platforms for scalability. The company has received multiple FDA designations such as Fast Track, Orphan Drug, Rare Pediatric Disease, and RMAT for various indications. Financially, the company reported a net loss of $167.9 million for the fiscal year ended December 31, 2025, with cash and equivalents totaling approximately $83 million. The company continues to invest heavily in clinical development and manufacturing scale-up while facing risks typical of early-stage biotechnology firms.

Arbutus Biopharma Corp operates in the biopharmaceutical sector, focusing on RNA interference (RNAi) therapeutics targeting chronic hepatitis B virus (cHBV) infection and other liver diseases. The company has shifted its strategy to concentrate on clinical development of two main product candidates, imdusiran and AB-101, after ceasing discovery and in-house research activities. It has a history of licensing its proprietary lipid nanoparticle (LNP) technology, including royalty interests in ONPATTRO, a drug commercialized by Alnylam. Arbutus generates revenue primarily from collaborations, licenses, milestone payments, and royalties. The company has undergone restructuring to streamline operations and reduce costs. It maintains a strong liquidity position with no outstanding debt as of the end of 2025. Arbutus faces typical biopharmaceutical risks including patent challenges, regulatory hurdles, and the need for continued funding to support development and commercialization efforts.

Bally's Corp is a Delaware-based global gaming, hospitality, entertainment, and technology company with operations spanning casino, interactive gaming, and lottery markets. It owns and operates 20 casinos globally, including in the US and UK, and offers a broad portfolio of gaming products such as traditional casino gaming, iGaming, online bingo, sportsbook, and free-to-play games. Bally's holds a majority interest in Bally's Intralot S.A., which operates lottery and gaming technology businesses in 39 jurisdictions worldwide. The company is developing major integrated resort projects in Chicago and The Bronx, New York, and holds development rights in Las Vegas. Bally's business is organized into four segments: Casinos & Resorts, Bally's Intralot B2B, Bally's Intralot B2C, and North America Interactive. The company has undertaken significant mergers and acquisitions in 2025 to expand its portfolio and geographic reach. Its technology platform includes proprietary and third-party solutions, with a focus on data analytics and responsible gaming. Bally's marketing strategy centers on targeted advertising, direct marketing, player development, entertainment, and a comprehensive loyalty program.

Envoy Medical, Inc. develops innovative hearing health technologies, focusing on fully implanted devices that leverage the ear's natural anatomy. Its first product, the Esteem FI-AMEI, is FDA-approved but commercially limited due to reimbursement classification. The company’s lead product candidate, the Acclaim CI, is a fully implanted cochlear implant designed to eliminate external components, offering potential benefits such as 24-hour use, hearing in water, reduced stigma, and wireless charging. The Acclaim CI is in pivotal clinical trials with 56 patients enrolled, aiming to demonstrate safety and efficacy. Envoy Medical operates manufacturing in Minnesota and relies on select suppliers. The company faces competition from established cochlear implant manufacturers and plans to commercialize the Acclaim CI upon FDA approval, with future international expansion contingent on regulatory clearances. As of December 31, 2025, Envoy Medical reported $241,000 in revenue, a net loss of $23.8 million, and limited liquidity with a current ratio of 0.54 [S1].

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware in 2018, with operations in Chicago and subsidiaries in Australia and Romania. The company develops targeted immunotherapies for cancer, focusing on its lead candidate, ateganosine, a telomere-targeting agent designed to induce cancer-specific immune responses. Ateganosine is in clinical development for advanced non-small cell lung cancer (NSCLC), including patients resistant to current checkpoint inhibitors. MAIA conducts clinical trials in multiple regions, including Australia, Europe, Asia, and the United States, with ongoing Phase 2 and Phase 3 studies. The company collaborates with Regeneron for supply of cemiplimab and with BeiGene (BeOne Medicines) for combination trials in other cancer indications. MAIA holds multiple patents covering its compounds and has received FDA Fast Track and rare pediatric disease designations. The company does not own manufacturing facilities and relies on third-party manufacturers. Financially, MAIA has incurred significant losses and has limited liquidity, with no revenues to date.

Pyxis Oncology is a clinical-stage biotechnology company advancing a novel antibody-drug conjugate (ADC) platform targeting the extradomain-B of fibronectin (EDB+FN), a splice variant highly expressed in the tumor extracellular matrix but minimally in normal tissues. The lead product candidate, micvotabart pelidotin (MICVO), is designed to deliver a microtubule inhibitor payload selectively to the tumor microenvironment, employing a three-pronged mechanism of action including direct cytotoxicity, bystander killing, and immunogenic cell death. The company is conducting Phase 1 monotherapy and combination trials in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. Preliminary clinical data demonstrate encouraging objective response rates and disease control rates in heavily pre-treated patient populations, with an acceptable safety profile. Pyxis Oncology retains worldwide rights to MICVO and plans to commercialize it upon regulatory approval, with potential collaborations to extend geographic reach. The company has a strong intellectual property portfolio licensed from Pfizer, the University of Chicago, and Biosion, and maintains a robust cash position as of the end of 2025.

Theravance Biopharma, Inc. is a biopharmaceutical company incorporated in the Cayman Islands with principal offices in South San Francisco, California. It is publicly traded on NASDAQ under the ticker TBPH. The company focuses on developing therapies for serious diseases, including neurogenic orthostatic hypotension related to multiple system atrophy (MSA). The company completed enrollment in a pivotal Phase 3 study for this indication in 2025. Financial disclosures as of the fiscal year ended December 31, 2025, show positive net income and strong liquidity ratios. Recent news highlights operational adjustments such as job cuts and clinical trial setbacks, including a significant stock price decline following a failed late-stage MSA study. Despite these challenges, some market analyses recognize the company as a strong growth and momentum stock.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody targeting IL-1β, currently in a Phase 2 clinical trial (LOTUS) for hidradenitis suppurativa (HS), a chronic inflammatory skin disease with significant unmet medical need. The LOTUS trial is a randomized, double-blind, placebo-controlled study evaluating efficacy and safety in approximately 250 adults with moderate to severe HS, with topline data anticipated in the second quarter of 2026. Avalo acquired abdakibart rights through the acquisition of AlmataBio in early 2024, including exclusive licenses from Eli Lilly and Leap Therapeutics. The company plans to advance abdakibart through pivotal Phase 3 trials pending Phase 2 results and is exploring indication expansion. Avalo does not have internal manufacturing facilities and relies on third-party contract manufacturers. The company has limited sales and marketing capabilities at present and may develop or partner for commercialization. Avalo faces competition from multiple pharmaceutical and biotechnology companies developing treatments for HS and related inflammatory diseases. Financially, Avalo reported a net loss of $78.3 million for 2025 and held approximately $98.3 million in cash and short-term investments as of December 31, 2025, with strong liquidity ratios supporting ongoing operations.

HomesToLife Ltd operates in the furniture industry, focusing on leather upholstered furniture such as sofas, armchairs, and recliners. The company distributes its products through a network of retail stores under six brand names across Europe, North America, and Asia. The business model includes export sales, leather trading, and retail sales, with export sales constituting the majority of revenue. The company completed a significant acquisition of HTL Marketing Pte Ltd in 2025, which added multiple subsidiaries in key international markets, enhancing its global market position. HomesToLife manages foreign exchange risk through hedging policies and faces concentration risks with major customers and related-party vendors primarily located in China. The company has a cybersecurity risk management program overseen by its Board and Audit Committee. HomesToLife completed its IPO in October 2024 and uses proceeds primarily for working capital and corporate purposes.

BioLineRx Ltd. operates as a biopharmaceutical company specializing in the development of therapies for oncology and rare diseases. Its lead product, APHEXDA (motixafortide), received regulatory approval in September 2023 for stem-cell mobilization in multiple myeloma. The company has strategically out-licensed motixafortide rights to partners Gloria (Asia) and Ayrmid (global excluding Asia for non-solid tumors), resulting in the cessation of its independent U.S. commercialization activities and a refocus on clinical development in Israel. BioLineRx retains development rights for motixafortide in solid tumors outside Asia, including ongoing clinical trials in pancreatic cancer. The company pursues growth through in-licensing additional assets with potential for differentiation and cost-effective development. Financially, BioLineRx reported modest revenues primarily from royalties and milestone payments, with ongoing net losses reflecting investment in research and development. The company maintains liquidity supported by cash reserves, equity offerings, and loan facilities. Management comprises experienced executives and a board with industry expertise.

Cartesian Growth Corp III is a Cayman Islands exempted blank check company incorporated in October 2024. It aims to complete an initial business combination with one or more high-growth companies, leveraging the extensive experience of its sponsor, Cartesian Capital Group, LLC, a global private equity firm. The company completed its IPO in May 2025, raising $276 million, which was placed in a trust account to fund the business combination. The management team focuses on acquiring companies with proven business models, significant transnational operations, and strong management teams. The company has entered into a business combination agreement with Factorial Inc., a company specializing in solid-state battery technology, with the transaction anticipated to close in mid-2026. The company currently has limited operating activities and no full-time employees prior to the business combination.

FinWise Bancorp operates through its wholly-owned subsidiary FinWise Bank, a Utah state-chartered bank supervised by state and federal regulators. The company’s business model centers on originating loans across multiple sectors including SBA 7(a), residential and commercial real estate, commercial leasing, and Strategic Programs loans originated via third-party fintech platforms nationwide. FinWise Bank operates one full-service branch in Utah but leverages technology and fintech partnerships to serve customers nationwide. The company earns interest income from loans held for investment and sale, program fees from Strategic Programs, and non-interest income from various banking services. Deposits, including brokered and institutional deposits, fund lending activities. FinWise Bancorp reported net income of $16.1 million for 2025, with total assets of $977.1 million and shareholders’ equity of $193.2 million. The company maintains liquidity with $163.4 million in cash and equivalents and has a stock repurchase program authorized through March 2026. Recent fintech partnerships and program launches support expansion in lending and payment solutions.

Lithium Argentina AG operates in the lithium mining and processing sector, focusing on producing battery-grade lithium products. The company underwent a corporate reorganization in January 2025, relocating its corporate jurisdiction from Canada to Switzerland. It is publicly listed on the NYSE and TSX under the ticker 'LAR'. The company’s operations include phased lithium production with a target of 153,000 tonnes per annum lithium carbonate equivalent. Capital expenditures for the project are substantial, estimated at over $3 billion USD. Financial disclosures indicate a net loss in 2025 and liquidity challenges with a current ratio below 1. The company has implemented a cybersecurity risk management program and complies with IFRS accounting standards. Recent market interest is reflected in mentions within green and clean energy ETFs and lithium sector investment news.

SUNation Energy, Inc. operates as a residential and commercial solar energy provider focused on New York and Hawaii markets. The company designs, installs, and maintains photovoltaic solar energy systems, battery storage solutions, and offers integrated roofing services. It serves primarily residential homeowners but also commercial, industrial, and municipal customers. SUNation Energy emphasizes a customer-centric approach with in-house installation teams and digital tools, achieving high referral rates. The company pursues growth through acquisitions and organic expansion, aiming to capitalize on industry consolidation. It offers financing assistance to customers and provides community solar and grid services, including virtual power plants in Hawaii. The company competes in a fragmented market with many small contractors and faces competition from utilities and other solar providers. SUNation Energy holds several trademarks and maintains relationships with major solar product vendors. The company has a seasoned management team with extensive industry experience.

Ashford Hospitality Trust, Inc. operates as a real estate investment trust (REIT) owning and managing a portfolio of upscale and upper upscale full-service hotels in the United States. The company’s portfolio includes 68 operating hotel properties primarily branded under Hilton, Hyatt, Marriott, and Intercontinental Hotel Group. It conducts its business through its operating partnership and is advised by Ashford LLC, a subsidiary of Ashford Inc., which provides asset management and other services. The company does not have employees and contracts hotel management companies to operate its properties. Its investment strategy targets hotels with revenue per available room (RevPAR) generally less than twice the U.S. national average, focusing on properties that offer current returns or value appreciation potential through repositioning or capital improvements. The company also pursues mezzanine financing, first mortgage financing, and sale-leaseback transactions as part of its lodging-related investment opportunities. Financing is a key component of its strategy, with significant use of debt to enhance equity returns. The company faces refinancing risks due to substantial property-level debt maturing within the next year and cash trap provisions on many hotels that restrict cash flow. It has a deficit in stockholders' equity and has suspended dividends on common stock, with no dividends expected in the foreseeable future. The company actively manages its portfolio through acquisitions, dispositions, and capital improvements to maintain asset quality and profitability.

Rubico Inc. is a shipping company listed on Nasdaq under the ticker RUBI since August 2025. The company operates a fleet of vessels including chemical/product oil carriers and yachts, managing these assets through agreements with related parties. Rubico pursues growth through acquisitions of new vessels, supported by shipbuilding contracts and financing arrangements such as sale and leaseback agreements. The capital structure includes common shares, multiple series of preferred shares, and warrants. The company has recently undertaken a reverse stock split and a public offering to raise capital. Financial disclosures show revenue generation and profitability as of the fiscal year ended December 31, 2025, with liquidity ratios indicating some short-term financial constraints.

Bitwise Chainlink ETF is an investment trust established under Delaware law with the objective of providing investors exposure to Chainlink cryptocurrency. The Trust issues shares listed on NYSE Arca under the ticker CLNK, facilitating market access to Chainlink price movements. The Sponsor, Bitwise Investments Advisers, LLC, a subsidiary of Bitwise Asset Management, Inc., manages the Trust, including marketing, registration, and operational oversight. The Trust's sole asset is Chainlink, and shares are created and redeemed in blocks of 10,000 with authorized participants through in-kind or cash transactions at net asset value. The Trust had no operational activity during 2025 except for seed capital issuance and organizational activities, holding $200 in cash as of December 31, 2025. The Sponsor assumes ordinary expenses and charges a management fee of 0.34% per annum on Chainlink holdings, with a fee waiver on the first $500 million of assets through April 13, 2026. The Trust does not hold significant cash balances and does not borrow to meet liquidity needs.

Benitec Biopharma Inc. is a Delaware-based biotechnology company listed on Nasdaq under the ticker BNTC. The company focuses on the development of novel gene therapies, including BB-301 targeting oculopharyngeal muscular dystrophy (OPMD). It operates as a single segment entity and has reported positive clinical trial results for BB-301 in Phase 1b/2a studies, demonstrating robust efficacy and durability of response. The company has no reported revenues and incurs net losses consistent with its early-stage development status. As of the end of 2025, Benitec Biopharma held substantial cash reserves and current assets, supporting its ongoing research and development activities. The company’s capital structure includes common stock and various warrants. It faces risks common to early-stage biotech firms such as regulatory approval uncertainty, competition, intellectual property protection, and the need for additional financing [S1][S2][N1][N3][N4].

Bitwise Dogecoin ETF is an investment trust established under Delaware law with the objective of providing investors exposure to Dogecoin's value, net of expenses. The Trust commenced operations on November 25, 2025, and its shares began trading on the NYSE Arca on November 26, 2025, under the ticker BWOW. The Trust's sole asset is Dogecoin, which it holds at fair value, and it operates as an investment company under U.S. GAAP. The Sponsor, Bitwise Investment Advisers, LLC, a subsidiary of Bitwise Asset Management, Inc., manages the Trust's operations, marketing, and regulatory compliance. The Trust pays a unitary Sponsor Fee of 0.34% per annum on Dogecoin holdings, with the Sponsor covering most ordinary operating expenses. The Trust does not hold significant cash balances except for creation and redemption activities and paying expenses not assumed by the Sponsor. The Trust's net assets were approximately $1.15 million as of December 31, 2025, with a net decrease in net assets from operations primarily due to realized and unrealized losses on Dogecoin investments driven by price depreciation. The Trust has no material legal proceedings or regulatory trading suspensions and maintains policies to prevent conflicts of interest and insider trading. The Trust's shares are created and redeemed in baskets of 10,000 shares by authorized participants who are registered broker-dealers or exempt from registration.

Duluth Holdings Inc. operates as a lifestyle brand offering innovative, durable, and functional men's and women's casual wear, workwear, and accessories. The company sells primarily through its omnichannel platform, which includes its website, catalog, and a network of retail and outlet stores. As of August 2025, Duluth operated 61 retail stores and 3 outlet stores. The brand emphasizes a modern, self-reliant American lifestyle with proprietary products such as Longtail T® shirts and Fire Hose® work pants. The company’s revenues are predominantly generated in the United States, and it reports a single operating segment aligned with its omnichannel approach. Duluth’s business is seasonal, with a significant portion of revenue and profit realized in the holiday quarter. The company manages risks related to supply chain, inventory, consumer demand, and competition.

Cheer Holding, Inc. operates a leading mobile and online advertising, media, and entertainment business in China, focusing on original lifestyle content and content-driven e-commerce platforms. The company produces various content including short videos, online variety shows, dramas, live streams, and the CHEERS series. Revenue is primarily derived from advertising services, copyright licensing, and the CHEERS e-Mall marketplace. The company has two main operating segments: CHEERS App Internet Business and Traditional Media Business. For the year ended December 31, 2025, the company reported revenues of approximately $148.8 million and net income of about $25.6 million. The company maintains strong liquidity with cash and cash equivalents of approximately $242.1 million and a current ratio of 11.53. Cheer Holding operates through subsidiaries and VIEs in China, with associated regulatory and operational risks. The company has a dual-class share structure and has recently undertaken share consolidations and capital increases. Management has disclosed material weaknesses in internal controls and is working on remediation.

AutoZone, Inc. operates as a leading retailer and distributor of automotive replacement parts and accessories across the Americas. The company manages a network of 7,657 stores as of August 2025, including locations in the U.S., Mexico, and Brazil. Its product offerings cover a broad range of automotive hard parts, maintenance items, accessories, and non-automotive products for cars, SUVs, vans, and light trucks. AutoZone serves both retail customers and commercial clients such as repair garages, dealers, and fleet owners through physical stores and online platforms. The company also markets automotive diagnostic and repair software under the ALLDATA brand. AutoZone's business model focuses on customer service excellence, supported by investments in supply chain infrastructure and technology. The company does not provide automotive repair or installation services. Fiscal 2025 net sales were $18.9 billion, with operating profit of $3.6 billion and net income of $2.5 billion. The company faces competition from various retail and online auto parts providers and operates in a dynamic environment influenced by economic conditions, labor market factors, and supply chain challenges [S1][S2].

Scholastic Corporation is a diversified publishing and media company focused on children's books, education solutions, entertainment content, and international markets. Its business segments include Children's Book Publishing and Distribution, which covers book clubs, book fairs, and trade channels in the U.S.; Education Solutions, providing print and digital educational materials and programs for pre-kindergarten to grade 12; Entertainment, which develops and licenses children and family film and television content; and International operations that distribute products and services outside the U.S. The company uses operating income as the key metric for segment performance evaluation. Recent financial disclosures show revenues of $329.1 million for Q3 2026 and net income of $62.5 million for the same period. Scholastic has engaged in sale and leaseback transactions of key properties and announced a substantial share buyback program, reflecting active capital management.

Standard Premium Finance Holdings, Inc. is a specialized insurance premium financing company that facilitates access to financing for commercial insurance premiums. Established in 1991 through its subsidiary, the company offers loans primarily between $1,000 and $100,000 with repayment terms of 6 to 11 months, occasionally extending to larger loans. The company operates in 41 states, having expanded from its original Florida base, and originates loans through a network of insurance agents and in-house marketing representatives. Revenue is generated mainly from interest income and fees calculated using the Rule of 78 method, a standard in the premium finance industry. Funding is sourced primarily from a secured line of credit, subordinated notes payable, and operating cash flow. The company maintains a strong liquidity position with a current ratio above 1.2 and has demonstrated growth in loan originations and revenue in recent years [S1].

Star Equity Holdings, Inc. is a publicly traded Delaware corporation with common and preferred stock listed on NASDAQ. The company operates through subsidiaries including Alliance Drilling Tools, LLC, which engages in real estate sale and leaseback transactions. Star Equity announced a definitive merger agreement with Hudson Global, Inc. to form a new company. The company maintains a focus on cybersecurity risk management with oversight from its board and audit committee, supported by an experienced Global Director of Information Technology and external consultants. Financial disclosures for the fiscal year ended December 31, 2025, show revenue of $172.2 million and a net loss of $5.9 million, with liquidity ratios indicating a current ratio of 2.1 and a cash ratio of 0.34.

Lightwave Logic, Inc. develops and commercializes proprietary electro-optic polymer materials engineered for integration into silicon photonics and photonic integrated circuits. These materials enable high-speed, high-bandwidth optical modulation with lower drive voltages and more compact device footprints compared to conventional technologies. The company’s business model focuses on material sales, intellectual property licensing, process design kit enablement, and royalty or fee-based arrangements tied to customer production. Customers include semiconductor foundries, device designers, optical module manufacturers, and system integrators serving AI, cloud computing, data center, and telecommunications markets. Commercial operations commenced in May 2023, with multiple customer programs progressing through a structured Design Win Cycle. Revenue recognized to date is limited, with significant volume production revenue not expected until 2027 at the earliest. The company maintains an extensive patent portfolio and strong liquidity as of December 31, 2025.

Urban One, Inc. operates in the media sector, with a focus on radio and cable businesses. The company is publicly traded on NASDAQ under the tickers UONE and UONEK. It completed a reverse stock split in early 2026. Financial disclosures show significant net losses in recent periods and a current liquidity position with a current ratio of 2.1 as of year-end 2025. Management has communicated challenges in advertising revenue and is actively managing debt and capital allocation. The company has amended credit agreements and issued senior secured notes to support its capital structure.

GrowGeneration Corp. is a Colorado-based company founded in 2014 that has expanded from a small chain of specialty hydroponic and organic garden centers into a multifaceted business with two main operating segments: Cultivation and Gardening, and Storage Solutions. The Cultivation and Gardening segment offers a wide range of products for indoor and outdoor hydroponic and organic gardening, including proprietary brands such as Charcoir, Drip Hydro, Power Si, Ion lights, The Harvest Company, and Viagrow. The company serves commercial, craft, and home growers in the plant-based medicine market and organic gardeners, distributing products through retail locations, commercial sales, wholesale channels, and an online platform. The Storage Solutions segment, branded as Mobile Media or MMI, provides customized storage systems and services to various industries including agriculture, retail, warehousing, hospitality, and controlled environment agriculture. GrowGeneration's growth strategy focuses on consolidating fragmented hydroponics assets, expanding proprietary brands, and optimizing its retail footprint. The company has undertaken a strategic restructuring plan since 2024 to improve profitability and operational efficiency. As of late 2025, GrowGeneration operates 23 retail locations across 10 states and continues to evaluate its retail presence. The company faces competition from numerous local and national vendors and online marketplaces but differentiates itself through product selection, proprietary brands, and customer service. Financially, the company reported a net loss in 2025 and maintains liquidity with a strong current ratio. It manages supply chain risks related to tariffs and sourcing and is exposed to regulatory uncertainties in emerging markets such as cannabis cultivation.

Affinity Bancshares, Inc. operates as a financial institution primarily engaged in lending activities including commercial real estate loans (both owner-occupied and non-owner-occupied), residential mortgages, and consumer loans. The company maintains a diversified loan portfolio and manages credit risk through allowances for credit losses. It holds significant cash and cash equivalents and deposits, supporting its liquidity position. The company is publicly traded on NASDAQ under the ticker AFBI.

SWK Holdings Corporation, headquartered in Dallas, Texas, focuses on specialty finance and asset management within the life sciences sector. The company’s Finance Receivables segment provides capital to life science companies through royalty purchases, debt financings, and synthetic revenue interests, primarily targeting commercial-stage products. The company fills an underserved niche by focusing on transactions under $50 million, where competition is less intense. Its portfolio includes senior and subordinated debt backed by royalties and revenue interests. The company’s strategy aims to generate income from royalties, interest, and equity-related investments while managing risk prudently. The Pharmaceutical Development segment was divested in 2025, leaving Finance Receivables as the sole operating segment. The company sources investment opportunities through management relationships and business development efforts. Competition includes various financial institutions and funds with greater resources, but SWK Holdings competes on experience, flexibility, and speed rather than price.

Armada Acquisition Corp. III is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands on September 19, 2025. The company was formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It has not yet selected a specific target for its initial business combination. The company intends to focus on businesses in the FinTech, SaaS, or AI sectors but is not limited to any particular industry or geography. The company completed its IPO on February 19, 2026, raising gross proceeds of approximately $248.5 million from the sale of units, with additional proceeds from a private placement. These funds are held in a Trust Account to be used for the initial business combination and related expenses. Until the business combination is completed, the company does not generate operating revenues but may earn non-operating income from interest and dividends on the Trust Account investments. The company incurs expenses related to being a public company and due diligence activities. It has no long-term debt and limited liabilities, primarily a monthly fee payable to its Sponsor for administrative services. The company’s shares trade on Nasdaq under multiple symbols representing units, ordinary shares, and warrants.